Also for asthma patients who need oral corticosteroids, where adding Asmanex
"may reduce or eliminate the need for oral corticosteroids.
It is possible that hypercorticism (an excess level of steroids in your body) or adrenal insufficiency (your adrenal gland cannot produce enough steroids) may appear in a small number of patients, particularly when ASMANEX
is administered at higher than recommended doses over prolonged periods of time.
Xopenex -- Foradil -- Serevent -- Arcapta/Onbrez -- Brovana -- Spiriva -- Atrovent -- Eklira/Tudorza/Bretaris -- Flixotide/Flovent -- Pulmicort -- QVAR -- Asmanex
-- Singulair -- Xolair -- Cinquil -- Mepolizumab -- Benralizumab -- Lebrikizumab -- Dupilumab -- Advair/Seretide -- Symbicort -- Combivent -- Dulera -- Breo/Relvar Ellipta
market, including ASMANEX
(mometasone furoate) for asthma and REMERON
Avoid coming in contact with measles, chicken pox virus, tuberculosis, or any other infections before or while using ASMANEX
Individuals should talk to their physician to identify and opt for more cost-effective and effective asthma drugs including maintenance inhalers such as Asmanex
, Pulmicort Flexhaler and Qvar, and rescue inhalers such as Ventolin HFA.
Schering-Plough Obtains Approval for Asmanex
in Japan II-44
Gained FDA approval of ASMANEX
TWISTHALER (mometasone furoate
Figure: Global sales of Nasonex and Asmanex
DULERA combines an inhaled corticosteroid medicine, mometasone furoate (the same medicine found in ASMANEX
TWISTHALER), and a long-acting beta2-agonist medicine (LABA), formoterol (the same medicine found in FORADIL[R] AEROLIZER[R]).
Mode of Action 39 Approvals 39 Patents 39 Generic Company Activity 40 Mylan 40 Actavis 40 Prasco Laboratories 40 Teva 41 US Generic Approvals 41 Market Outlook 41 Asmanex
Twisthaler (mometasone furoate) 43 Mode of Action 43 Approvals 43 Patents 44 Generic Company Activity 44 Market Outlook 44 Alvesco (ciclesonide) 46 Mode of Action 46 Approvals 46 Patents 46 Generic Company Activity 47 Market Outlook 47 Combivent (ipratropium bromide+ salbutamol[albuterol]) 48 Mode of Action 48 Approvals 48 Patents 48 Generic Company Activity 49 Market Outlook 49 Spiriva (tiotropium bromide) 51
SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including statements relating to the development and potential market for combination products including ASMANEX
and the TWISTHALER device.